Evidence map›Paper›PMID 37446639›Full record

ArticleMolecules (Basel, Switzerland)2023

Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9).

Bei Qin, Lili Yu, Rong Wang, Yimei Tang, Yunmei Chen, Nana Wang, Yixin Zhang, Xiong Tan, Kuan Yang, Bo Zhang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Bei QinXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.ORCID 0000-0003-0015-7676
Lili YuXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Rong WangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Yimei TangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Yunmei ChenXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Nana WangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Yixin ZhangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Xiong TanXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Kuan YangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.ORCID 0000-0003-4834-8084
Bo ZhangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Maofang HeXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Yuzhen ZhangXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Yaqi HuXi'an Key Laboratory of Multi Synergistic Antihypertensive Innovative Drug Development, Xi'an Medical University, Xi'an 710021, China.
Xi'an Medical University · CNChengdu Medical College · CN

Funding

Shaanxi University Youth Innovation Team Construction Project Shaanxi Jiaohan [2022] 943the Key Research and Development Program of Shaanxi 2021ZDLSF03-05the Scientific and Technological Innovation Team project of Xi'an Medical University 2021TD03, 2021TD09
6 · The paper itself

Abstract

Hypertension is the main risk factor of cardiovascular and cerebrovascular diseases. In this paper, a novel compound known as 221s (2,9), which includes tanshinol, borneol and a mother nucleus of ACEI, was synthesized by condensation esterification, deprotection, amidation, deprotection, and amidation, with borneol as the initial raw material, using the strategy of combinatorial molecular chemistry. The structure of the compound was confirmed by

Indexed as

Antihypertensive AgentsHypertensionAnimalsBlood PressureCamphanesMyocytes, CardiacRatsRats, Inbred SHRAntihypertensive AgentsCamphanesisoborneolACEIantihypertensiveborneolRAAStanshinol

Identifiers

PMID37446639
PMCPMC10343876
OpenAlexW4382060604

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.